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Abstract
Background: Next generation sequencing and advances in genomic enrichment technologies have enabled the
discovery of the full spectrum of variants from common to rare alleles in the human population. The application of
such technologies can be limited by the amount of DNA available. Whole genome amplification (WGA) can overcome
such limitations. Here we investigate applicability of using WGA by comparing SNP and INDEL variant calls from a
single genomic/WGA sample pair from two capture separate experiments: a 50 Mbp whole exome capture and a
custom capture array of 4 Mbp region on chr12.
Results: Our results comparing variant calls derived from genomic and WGA DNA show that the majority of variant
SNP and INDEL calls are common to both callsets, both at the site and genotype level and suggest that allele bias
plays a minimal role when using WGA DNA in re-sequencing studies.
Conclusions: Although the results of this study are based on a limited sample size, they suggest that using WGA
DNA allows the discovery of the vast majority of variants, and achieves high concordance metrics, when comparing to
genomic DNA calls.
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Background
There has been considerable focus in human genetics
on characterizing rare variation in the human popula-
tion, and the role these variants play in human diseases
to account for the “missing heritability” in genome-wide
association studies using common variants [1,2]. Until
recently, the discovery of genetic variants was the rate-
limiting step due to the prohibitive cost of sequenc-
ing large numbers of samples using traditional Sanger
sequencing. Over the past five years, next generation
sequencing (NGS) technologies have replaced traditional
Sanger sequencing as the predominant method of DNA
sequencing [3,4]. The main advantage of NGS over tra-
ditional Sanger sequencing is its cheaper cost and higher
throughput. NGS has had a profound impact on the field
of human genetics because it is now possible to sequence
large numbers of individuals to fully describe the spec-
trum of human genetic variation, from common to rare
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variation [5]. In parallel to the developments of new
sequencing technologies, improved methods have been
developed to enrich specific subsets of the genome for
next generation sequencing. While commonly referred to
as exome sequencing, because in many cases protein cod-
ing regions have been enriched, in fact any portion of the
genome can be chosen for target enrichment [6,7]. Cap-
ture sequencing allows many individuals to be sequenced
for particular regions of interest, as opposed to whole
genome sequencing a smaller number samples at the
same cost [8]. This also provides greater sensitivity for
SNP detection compared to whole genome sequencing
[9]. Exome capture sequencing has yielded many suc-
cessful examples for uncovering causative mutations in
Mendelian disease [10,11], and describing the full extent
of rare variation in protein-coding portions of the genome
that whole genome sequencing may have missed because
high-coverage, whole genome sequencing is still not com-
mon practice [12].
While the discovery of genetic variation is no longer a
rate-limiting step for human genetic analysis, the appli-
cation of NGS and sequence capture technologies can be
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limited by the amount of DNA available [13]. In particu-
lar, probands that have been collected for a clinical study
maybe difficult to sample again. Previously collected DNA
samples gradually decay in quality over time, and non-
invasive collection techniques, such as buccal swabs, may
result in insufficient amounts of DNA [13]. Several rounds
of NGS or capture array sequencing may deplete original
stock aliquots of samples. Whole genome amplification
(WGA) is a method to overcome such challenges, and can
yield micrograms of WGA DNA from nanogram starting
amounts of template.
Previous studies have shown that WGA DNA per-
forms well on high-density SNP genotyping arrays
[14-16]. Three recent studies have investigated the use
of WGA DNA in NGS. Murphy et. al. [17] investigated
the use of a WGA protocol performed in situ on laser
capture micro-dissection cancer cells for the discovery
of structural variants in a tumor genome using Illumina
mate-pair sequencing. Tao et. al. [18] showed that WGA
DNA has favorable sequence capture metrics when com-
paring to genomic DNA when adapting the NimbleGen
capture array for use on the Illumina GA sequencing plat-
form. El Sharawy et. al. [19] investigated the use of WGA
DNA in a NGS microdroplet-based PCR sample enrich-
ment pipeline experiment of 384 exons with 3 HapMap
samples. They showed there was strong genotype con-
cordance with both genomic and WGA DNA SNP calls
to HapMap III genotypes. In this paper we describe the
results of variant calls using WGA DNA for a single sam-
ple for two separate capture sequencing experiments on
the Agilent SureSelect platform, and compare them to
variant calls made with genomic DNA for the same sam-
ples. While the results in this study are based on a limited
number of samples, our results suggest thatWGA samples
have a high sensitivity in detecting variant alleles identi-
fied with genomic DNA, and can be used effectively in
re-sequencing studies.
Results and discussion
Capture metrics of WGA and genomic DNA
We analyzed capture sequencing metrics of genomic and
WGA sample pairs for two capture experiments, a chr12
custom array and a whole exome capture array. Additional
file 1 contains capture metrics from the program Cal-
culateHsMetrics from the software package Picard [20].
The average target coverage for the whole exome capture
experiments were 92x (WGA) and 80x (genomic). The
average target coverage for the chr12 capture experiments
were 432x (WGA) and 224x (genomic). WGA samples
in both capture experiments had a higher number of PF
(passed filter) reads thus higher average target because
they were sequenced in a separate flow-cell lane, while
the genomic DNA samples were multiplexed. For both
sequencing experiments a large percentage of reads were
marked as duplicates, as the percentage of usable bases on
target for each of the capture experiments does not exceed
40%. Despite the high duplicate read fraction both samples
in the whole exome capture experiment had 80% targeted
of bases with at least 20x coverage. For the smaller chr12
capture experiment, over 90% of targeted bases had at
least 20x coverage.
Since the WGA capture experiments had a larger
sequencing library compared to the genomic, a random
subset of reads were selected from the starting fastq files
to match the number of PF reads of the genomic sequenc-
ing library (see Additional file 1 and Methods). The aver-
age target coverage for the chr12 WGA subsetted BAM
(342x) is higher than the chr12 genomic experiment, even
though the starting number of PF reads is the same. This
can be attributed to higher percentage of usable bases
on target, as calculated with HsMetrics. Similarly, the
whole-exome WGA subsetted BAM average target cover-
age (63x) is less than the genomic sample, despite starting
with the same number of PF reads. The percent usable
bases on target are lower in the whole-exomeWGA subset
than the whole exome genomic sequencing experiment.
Next, we explored the relationship between GC% and
median target coverage for both capture experiments.
Previous studies have shown that lower sequencing cov-
erage occurs in regions with high GC% [21]. GC% of
targets for each capture experiment was calculated. Next,
the targets were placed in four bins according to the first,
median, and third quartiles of capture target GC%, based
on the boxplots shown in Additional file 2: Figure S1. In
addition to boxplots of GC% of capture targets of the two
experiments, Additional file 2: Figure S1 shows the GC%
of the whole genome and chr12 for comparison. Targets
were placed in the appropriate bin and within each bin, a
box plot of median target coverage was made for genomic
and WGA DNA, as shown in Figure 1. The results show
that for genomic DNA, chr12 capture targets in the fourth
bin (with GC% greater 51%) have lower coverage than tar-
gets in the other three bins. For the corresponding WGA
DNA, targets in the first (GC% less than 38%) and fourth
bins have a similar distribution of median target cover-
age. Whole exome capture targets in the fourth bin (GC%
greater 59%) had lower amounts of coverage than targets
with lower GC% for both genomic and WGA samples.
Since the chr12 capture targets were over a much smaller
interval (3.87 Mbp), its harder to make any definitive
statement regarding GC% and lower sequencing coverage,
but the patterns of coverage seen in both capture exper-
iments examined here are in line with previous studies
[9,21].
Overall variant counts and Venn analysis
Table 1 shows the counts and callset metrics of the indi-
vidual SNP and INDEL callsets, after post-call filtering
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Figure 1 Boxplots of median target coverage. Boxplots of median coverage of targets binned according to quartiles of GC% of capture targets
for chr12 and whole-exome capture experiments.
(described in theMethods). For all SNP callsets the dbSNP
fraction is 98%. The overall transition-transversion (TsTv)
ratio for theWGA and genomic chr12 callsets are 2.42 and
2.41 respectively. The overall TsTv ratio for the WGA and
genomic whole-exome callsets are 2.83 and 2.82, respec-
tively. The TsTv values of novel SNPs found in each of the
capture experiments is considerably reduced, suggesting
these may be false positive calls.









SNPs 4642 4592 29600 30316
dbSNP% 98.4 98.6 98.6 98.6
TsTv overall 2.42 2.41 2.83 2.82
TsTv novel 1.47 1.48 1.81 1.89
TsTv known 2.44 2.43 2.85 2.84
INDELs 491 482 2197 2215
dbSNP% 34.8 34.0 34.2 34.8
Read coverages, SNP and INDEL summaries.
We performed Venn analysis of the WGA and genomic
callsets to see how variants overlapped based on coor-
dinate intersection. Figure 2 shows four Venn diagrams
for SNP and INDEL sites in each of the capture experi-
ments. Visual inspection indicates there is a high fraction
of site-level concordance of SNP calls, with 97% and 99%
of the union of SNP sites lying in the intersection for the
whole exome and chr12 capture callsets. Slightly lower
numbers of 87% and 90% were found for INDEL sites.
Overall TsTv ratios for SNPs in the intersection were sim-
ilar to those calculated for each individual callset. TsTv
ratios of novel sites were slightly higher in the intersec-
tion, when compared to the original callsets. The TsTv
values of the genomic and WGA unique fractions for the
whole-exome capture experiment are considerably lower,
suggesting these are lower quality calls. The unique frac-
tions of the chr12 capture experiment are much smaller,
making it difficult to interpret the differences in value of
their TsTv ratios.
Downsampling alignments and subsetting reads
Since the WGA samples were run as a single lane but
the genomic samples were multiplexed, we downsampled
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Figure 2 Venn diagrams of SNP and INDEL variant calls. Venn diagrams of SNP and INDEL variant calls. The top row also shows TsTv ratios and
dbSNP fractions of SNPs in each portion of Venn diagram. The notation A\B means elements in callset A but not in callset B( i.e. unique to fraction A).
reads from each BAM to examine the effect of coverage on
the numbers of discovered variants. A total of 100 boot-
strap sub-samples of reads were performed (seeMethods).
In addition to downsampling the reads from the aligned
BAM file, a subset of fastq reads were chosen at random to
match the starting number PF reads in the genomic library
for both experiments (see Additional file 1).
Figure 3 shows the median number of variants discov-
ered as a function of average target coverage for SNPs
and INDELs, for each capture experiment. The randomly
chosen subset of WGA reads to match the number of
PF reads in the genomic sequencing experiment is shown
as genomic.matched on the x-axis, and sorted in ascend-
ing order of target coverage. As expected, downsampling
BAMs reduces the number of called variants, with the
original WGA BAM having the largest number of called
variants. The datapoint that most closely matches the tar-
get coverage of the non-WGA sample is 80x for the whole-
exome plot. The median number of SNPs and INDELs
found (29350 and 2174) closely match the numbers of
variants found the in genomic derived variant calls listed
in Table 1. The datapoint that most closely matches the
target coverage non-WGA sample is 200x for the chr12
plot. The median number of SNPs and INDELs found
(4615,483), again closely match what was found in the
genomic derived calls listed in Table 1.
Genotype concordance
We used two measures of genotype concordance, non-
reference sensitivity (NRS) and non-reference discrepancy
(NRD) [22,23], shown in Additional file 3: Figure S2, to
compare genotypes made with WGA and genomic DNA.
NRS measures the proportion of sites called variant in
the comparison callset (genomic) that are also called vari-
ant in the evaluation callset (WGA). NRD measures the
proportion of differing genotypes between the WGA and
genomic callsets, at sites called in both data sets, excluding
concordant homozygous reference calls.
The NRS and NRD values for SNPs and INDELs for
each capture experiment are shown in Table 2 and the
concordance matrices from which they were calculated
are shown in Additional file 4: Figure S3. For the chr12
capture experiment, of the 17 sites that contribute to
the decrease in SNP NRS of the WGA call set, six are
heterozygous sites in the genomic DNA that were not
called in WGA DNA. Of the 28 sites contributing to the
decrease in INDEL NRS, 18 were heterozygous genotypes
in genomic DNA, that were evenly split as homozygous
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Figure 3 Number of variants discovered in downsampled and subsettedWGA BAMs.Median number of SNPs and INDELs called from 100
bootstrap subsampled BAM files from whole-exome and chr12 capture experiments for WGA DNA samples. Plot also includes number of variants
discovered in the WGA subsetted BAM that matched the starting read count of the genomic sample.
reference or no calls in WGA DNA. For the 13 sites con-
tributing SNP NRD, eight were WGA heterozygous sites,
called homozygous non-reference in genomic DNA. The
greatest contribution to INDEL NRD came from sites that
were called heterozygous inWGADNA, but homozygous
reference in genomic DNA.
Next, genotype concordance for each bootstrap down-
sampled chr12 capture BAMwas calculated by comparing
its calls to the ones made from the original genomic BAM
file. NRS and NRD values were summarized by calculat-
ing their median value across all 100 downsampled BAMs.
In addition, NRS and NRD of the subsetted WGA BAM
was calculated by comparing its genotypes to the original
genomic BAM. Figure 4 shows the affect of downsam-
pling and subsetting on genotype concordance metrics.
Unexpectedly, two of the three downsampled datasets
have slightly higher SNP and INDEL NRS values than the
original WGA callset. This includes the NRS of the 200x
downsampled BAM, which most closely matches the cov-
erage of the genomic sample. Similarly, the original WGA
Table 2 Genotype concordancemetrics
Dataset NRS NRD
whole-exome capture SNPs 98.28 0.63
whole-exome capture INDELs 91.17 13.46
chr12 capture SNPs 99.63 0.29
chr12 capture INDELs 94.07 10.7
NRS and NRD values for WGA derived whole-exome and chr12 capture call sets
when comparing to genomic call sets.
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Figure 4 Genotype concordance metrics of downsampled subsettedWGA BAMs.Median values of NRS and NRD metrics for SNP and INDEL
variants calculated from 100 bootstrap subsampled BAM files from whole-exome and chr12 capture experiments for WGA DNA samples. Plot also
includes NRS and NRD metrics of the WGA subsetted BAM that matched the starting read count of the genomic sample.
callset has a higher NRD values than some of the lower
coverage, downsampled BAMs (including the 200x down-
sample BAM). The INDEL NRD for the genomic matched
WGA BAM is clearly an outlier on the graph. This might
be attributed to sampling error, but since the WGA fastq
files were subsetted only once, its difficult to say. This
unexpected pattern can potentially be attributed to the
smaller capture interval in the chr12 experiment and
the fewer numbers of variants called, as the relationship
between concordance metrics and lower coverage, down-
sampled BAMs is clearer in the whole-exome capture
experiment (see below). Also, since a technical replicate
of genomic sequencing was not performed, it’s difficult
to ascertain what the expected genotype discrepancies
should be between genomic and WGA derived variant
calls.
The NRS and NRD values and the genotype con-
cordance matrix from which they were calculated for
the whole-exome capture experiment are also shown in
Table 2 and Additional file 4: Figure S3, respectively.
Of the 498 sites that contribute to the decrease of SNP
NRS of the WGA call set, the majority come from sites
either called heterozygous or homozygous non-reference
in genomic DNA but were no calls in WGA DNA. The
majority of sites contributing to the decrease of INDEL
NRS come from sites called heterozygous in genomic
DNA, but called homozygous reference in WGA DNA.
Sites contributing most to SNP NRD are heterozygous
calls in genomic DNA, called homozygous reference in
WGA DNA, for both SNP and INDEL variants. The con-
cordance metrics of the WGA whole exome downsam-
pled BAMs to original genomic DNA calls, also shown
in Figure 4, reinforce the intuitive expectation that the
lower coverage WGA callsets result in higher NRD and
lower NRS values. The one exception is the SNP NRS
of the genomic matched subsetted WGA BAM, which
had a NRD value of 2%. This could be attributed to sam-
pling error, since the subsetting was only performed once,
and not multiple times like the downsampling. The SNP
and INDEL NRS of the downsampled 80x BAMs, which
match the average coverage of the genomic BAM, are
only slightly lower than the original WGA BAM. Also, the
SNP and INDEL NRD values are slightly higher than the
original WGA BAM. Still, in each comparison, the orig-
inal WGA call set had the lowest NRD and highest NRS
values relative to lower coverage downsampled and sub-
setted callsets. As with the chr12 experiment, the genomic
sequencing was not repeated, so it difficult to quantify
the expected genotype discrepancies and sensitivity of the
WGA derived variant calls.
Targets with higher amounts of GC% have lower
amounts of median target coverage for both capture
experiments and both types of DNA, as described above.
Figure 5 shows NRS and NRD metrics for each bin, based
on GC% of targets. For the original WGA whole-exome
callset, the greatest number of genotype discrepancies and
lowest detection sensitivities, for both SNP and INDEL
variants, occur in targets with the highest GC%. The pat-
terns are less clear for the original WGA chr12 callset,
again most likely attributable to the smaller size of capture
region. For both SNP and INDEL variants, the greatest
numbers of genotype discrepancies are in targets with the
highest GC%. The pattern is less clear for variant detec-
tion sensitivity, INDELs in target regions with the highest
amount of GC% have the lowest sensitivity, but this is not
true for SNPs.
Allele bias in SNP variant calls
To investigate whether there is any evidence of allele
bias in SNP variant calls, all calls from the original
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Figure 5 Genotype concordance metrics as a function of GC%. NRS and NRD of variants binned according to GC% based on quartiles of GC% in
capture targets. First row shows NRD values for SNP and INDELs and second row shows NRS values of SNPs and INDELs for each of the chr12 and
whole-exome capture experiments.
chr12 and whole-exome WGA datasets were divided into
four groups: concordant genotypes, unique genomic calls
(these are sites that contribute to NRS), discordant geno-
types (these are sites that contribute to NRD), and WGA
unique. In each group, the percentage of each six possi-
ble reference/alternate allele combinations was calculated.
The results are shown in Figure 6. We tested to see if
there were statistically different proportions of each refer-
ence/alternate allele combinations (seeMethods) between
the four groups. The resulting p-values are in Additional
file 5. For the whole-exome capture SNPs, there was a sig-
nificant difference in proportion between concordant CG
SNPs and each of the three other categories. Also, there
was a significant difference in proportion of GT SNPs
between concordant andWGA unique categories. For the
chr12 capture set there was no significant difference in
proportion of SNPs between any of the four categories
for each of the 6 different allele combinations. The inter-
pretation of the statistical analysis of allele bias must be
tempered by the fact that the analysis is based on a small
sample size of matched genomic / WGA samples, lack of
technical replicates, and the reduced target region for the
chr12 capture experiment. But even with this in mind,
results suggest that allele bias does not play a significant
role in SNP variant discovery with WGA DNA.
Validation of SNP variant calls
Sequencing derived SNP variant calls were validated by
comparing genotypes to Affymetrix 6.0 Human SNP array
genotypes for the same sample. The 6.0 array has over
900,000 variants covering the whole genome, hence only
those array genotypes that overlapped a capture target
interval were examined. For the whole-exome capture
array there were a total of 11831 overlapping SNPs and
for the custom chr12 capture array there were a total
of 1435 overlapping SNPs. See the Methods section for
more details. The NRS and NRDmetrics of theWGA and
genomic sequencing based SNP genotypes when com-
pared to Affymetrix 6.0 SNP array genotypes for both
capture experiments is shown in Table 3. The NRD for
theWGAwhole-exome capture sequencing derived geno-
types when compared to the SNP array genotypes is
1.3% and the NRS value is 97.78%. The NRD for the
genomic whole-exome capture sequencing derived geno-
types when compared to the SNP array genotypes is 1.6%
and the NRS value is 97.66%.
The concordance matrix for the WGA whole-exome
comparison to capture array genotypes is shown in the
top panel and the genomic concordance matrix is shown
in the bottom panel in Additional file 6: Figure S5. For
sites that contribute to a decrease in whole-exome capture












































Figure 6 Allelic proportions of SNPs. Allelic proportions of whole-exome and chr12 capture SNPs in each of four categories: concordant
genotypes, unique sites in original genomic and WGA call sets, and discordant genotypes contributing to NRD for chr12 and whole-exome capture
experiments when comparing WGA derived SNP genotypes to genomic DNA callset.
NRS, the read coverage and pileup of bases was investi-
gated. For the 94 sites in the WGA whole-exome capture
call set that contribute to a decrease in NRS, 20 had mini-
mal coverage and were called homozygous reference. The
remaining sites have an overwhelmingmajority reads with
mapping quality 0 spanning the SNP position and were
not called. Similarly, for the 100 sites that contribute to
the decrease in NRS in the genomic DNA whole-exome
capture derived genotypes, 29 had minimal coverage and
were called homozygous reference. The remaining sites
had reads spanning the SNP position with mapping qual-
ity values of zero and not called. There are a total of
68 SNP positions common to both WGA and genomic
callsets that contribute to a loss of NRS when comparing
the Affymetrix SNP array genotypes.
Table 3 Affymetrix SNP array genotype concordance
metrics
Dataset NRS NRD
WGA whole-exome capture SNPs 97.78 1.30
Genomic whole-exome capture SNPs 97.66 1.60
WGA chr12 capture SNPs 82.60 22.20
Genomic chr12 capture SNPs 83.00 22.60
NRS and NRD values for whole-exome and chr12 capture call sets when
comparing to Affymetrix 6.0 genotypes.
The NRS and NRD values when comparing the WGA,
chr12 capture sequencing SNP genotypes to the SNP
array genotypes are 82.6% and 22.3%. The NRS for the
genomic DNA, chr12 capture SNP genotypes when com-
pared to SNP array genotypes is 83% and the NRD
is 22.6%. The concordance metrics for the chr12 cus-
tom array SNP genotypes when compared to the SNP
array derived genotypes is shown in Additional file 7:
Figure S6. The top panel shows the concordance matrix
for the WGA chr12 capture array and in the bottom panel
is the genomic chr12 concordance matrix. For both com-
parisons, the majority of sites that contribute to the loss
of sensitivity in the sequencing derived SNP calls are sites
that were called heterozygote on the genotyping array.
Careful visual inspection and examination of read pileups
in theWGA and genomic BAM files revealed no evidence
of an alternate allele and hence were called homozygous
reference. There are total of 144 SNP position common
to both WGA and genomic call sets that contribute to a
loss NRS when comparing to the Affymetrix SNP array
genotypes.
Allele bias in SNP variant validation calls
To investigate if there were any biases in the comparisons
of the sequencing derived genotypes to the Affymetrix
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array based genotypes the percentage of each six possible
reference/alternate allele combinations was calculated in
sites that contributed to concordant, NRS, and NRD cat-
egories. The results are shown in Figure 7. To test if
there were statistically different proportions of each ref-
erence/alternate allele combinations between groups we
applied the same pairwise.fisher.test when comparing the
WGA derived SNP calls to the genomic derived SNP
calls (see Methods). The resulting p-values of the analy-
sis are in Additional file 5. The only significant differences
in proportion detected were AT SNPs when comparing
the chr12 genomic and whole exome capture calls to the
corresponding Affymetrix array derived genotypes.
Conclusions
The study described here provides an in-depth assess-
ment of the suitability of WGA DNA for targeted rese-
quencing and variant discovery using next generation
sequencing.We evaluated whole exome as well as targeted
genomic enrichment using Agilent SureSelect technol-
ogy, and compared findings fromWGA samples to results
obtained with genomic DNA from the same individual,
as well as validated a subset of SNP variant calls with
Affymetrix SNP array genotypes. Overall, Venn analysis
showed that the numbers of SNPs and INDELs called in
the whole exome and chr12 capture callsets using WGA
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Figure 7 Allelic proportions of Affymetrix SNPs. Allelic proportions of whole-exome and chr12 capture SNPs in each of 3 categories: concordant
genotypes, NRD contributing, and NRS contributing for chr12 and whole-exome capture experiments when comparing WGA and genomic SNP call
sets to Affymetrix SNP array genotypes.
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of variant sites shared between datasets. The concor-
dance metric NRS demonstrates that using WGA DNA
has high sensitivity for SNP sites with values of 98.28%
and 99.63% for the whole exome and chr12 sequence cap-
ture callsets, respectively. The NRS for INDELs is lower
at 91.17% and 94.07%. SNP NRD values for the whole-
exome and chr12 callset were both less than 1%, but
were an order of magnitude higher for INDEL calls. The
lower values of these metrics may be due to slight differ-
ences in alignment of reads between genomic and WGA
DNA in regions that contain INDEL variants. The major-
ity of discrepant genotypes between WGA and genomic
DNA involve heterozygous genotypes and statistical anal-
ysis suggests that these are enriched for GC alleles, at least
in the whole-exome capture data. Validating a subset of
the SNP made with genomic and WGA DNA that overlap
sites on the Affymetrix 6.0 SNP array showed high sen-
sitivity and high genotype accuracy for the whole exome
capture callset. The sensitivity and genotype concordance
numbers for the chr12 capture array were not as high,
but the loss of sensitivity can be explained by lack of evi-
dence of the alternate allele in the read pileup or poor
zero mapping quality values spanning the SNP position.
Downsampling and subsetting of reads to achieve lower
coverage in WGA callsets (or match the starting number
reads in the genomic sequencing experiment) consistently
resulted in lower genotype concordance and sensitivity
metrics for the whole exome capture experiment, in con-
trast to the chr12 capture experiment. This difference
may be due to statistical fluctuations of read sampling
in the downsampling process, combined with the much
smaller size of the chr12 capture region. Coverage and
concordance metrics correlated with GC% of target inter-
vals, with target intervals above the 3rd quartile of each
respective capture array having less coverage and poorer
concordance metrics. Our work complements the study
of ElSharawy [19] who used a greater number of matched
genomic / WGA samples in showing both genomic and
WGA samples had high concordance and sensitivity met-
rics to HapMap III sites, but whose study examined only
384 exons. A limitation of our study is that we only have 1
genomic/WGA sample pair for each of the capture experi-
ments, and the chr12 experiment captured amuch smaller
region of genomic DNA. Since the genomic sequencing
was not repeated, we cannot know the expected dis-
crepancy for a technical replicate, but we were able to
validate a subset of our SNP calls that overlapped sites on
the Affymetrix SNP array. Thus, our conclusions about
allele bias, and the relationship between GC% content
and genotype concordance must be taken with caution,
but overall suggest that WGA samples can be used effec-
tively in re-sequencing studies and thus offer a promising
alternative for variant discovery studies using archived
DNA.
Methods
WGA and genomic DNA sample preparation
Two sample sets were analyzed in this study. One sam-
ple was from a family cohort [24] that was sequenced
for a 3.87 Mbp region on chr12 using a custom designed
SureSelect capture array from Agilent. The second sample
was from a single family that was whole exome sequenced
using the Agilent SureSelect All Exon kit. In both cases,
the genomic DNAwas originally isolated from blood sam-
ples. A REPLI-g Mini Kit (Qiagen) was used to prepare
WGA DNA from 15 ng of starting genomic DNA.
Sequence capture
We used two different Agilent SureSelect kits to perform
sequence capture on the samples used in this study. The
first was a custom array designed to capture a 3.87 Mbp
region on chromosome 12. The second was an Agilent
SureSelect All Exon kit designed to capture at total of 49.4
Mbp of exonic sequence spanning the whole genome. The
standard Agilent SureSelect protocol for Illumina paired-
end sequencing was used which requires 3 of micrograms
of starting genomic DNA.
DNA sequencing
Samples were paired-end sequenced on an Illumina GAII
machine with read lengths of 101 bp. with insert size
for the genomic and WGA whole exome capture sam-
ples being each 370 bp, respectively. Insert sizes for the
genomic and WGA chr12 capture samples were both 320
bp, respectively. Both sets of genomic DNA samples were
multiplexed with other samples not part of this study,
while each of the corresponding WGA DNA samples
were sequenced in an individual flow cell lane. Fastq files
were generated via the Illumina CASAVA pipeline v1.8.
The starting number of passed filter reads is shown in
Additional file 1, as well as additional metrics of capture
experiments.
Bioinformatics pipeline
We applied the same bioinformatics pipeline to WGA
and genomic DNA samples as shown in Additional file 8:
Figure S4. All programs from the Genome Analysis
Toolkit (GATK) were from version v1.6-5-g557da77 [22].
All programs from Picard were from v1.50 [20]. Fastq files
were aligned to the human reference sequence GRCh37
with the program MOSAIK v2.0.113q [25]. Parameter
values to MosaikAligner were as follows: -act 35, -bw
37, -mhp 200 -mm 14. Capture metrics for the whole
exome and chr12 capture experiments were calculated
using the program CalculateHsMetrics in Picard. Base
quality scores were recalibrated with the GATK programs
CountCovariates and TableRecalibration. PCR duplicates
were marked using the programMarkDuplicates, which is
part of Picard. SNP and INDEL variants were discovered
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using the GATK program UnifiedGenotyper. Parameters
used for running UnifiedGenotyper were as follows: -
stand_call_conf: 10, -stand_emit_conf: 30, -glm: BOTH,
-out_mode: BOTH, -hets: .001. Each member of the
WGA/genomic sample pair was called independently as
a single sample. UnifiedGenotyper was given the tar-
get capture intervals of each experiment and only made
variant calls in these intervals when calling INDEL and
SNP variants. SNP variant calls were filtered using the
GATK program VariantFiltration with the following filter-
ing parameters:
((MQ0/(1.0∗DP)) > 0.05) || DP<5 || QUAL<30.0 || QD
< 5.0 || HRun > 5.0 || SB ≥ − 0.10
INDEL variant calls were filtered with the following:
((MQ0/(1.0∗DP)) > 0.05) || SB ≥ −1.0 ||QUAL < 10
Where MQ0 = Number of reads with mapping qual-
ity zero, DP = depth of coverage, QUAL= Phred scaled
quality score, HRun = Largest contiguous homopolymer
run of variant allele in either direction, QD = Variant
Confidence/Quality by Depth, and SB = Strand Bias.
Downsampling and subsetting of reads in WGA and
genomic BAM files
To investigate the relationship between sequence cover-
age and number of variants discovered, aligned reads from
bothWGA BAM files were downsampled to different lev-
els average target coverage using the Picard v1.50 program
DownsampleSam. Since UnifedGenotyper restricted its
variant calling to target capture interval regions, only
aligned reads that had a minimum 1-bp overlap with
a target interval were considered in the downsampling
process by removing off target alignments by using the
pairToBed program in BEDTools package [26] For the
chr12WGABAM, 100 downsampled BAM files were gen-
erated with average target coverages of 100x, 200x and
300x, respectively. For the whole-exome WGA BAM, 100
downsampled BAM files were generated at coverage lev-
els of 20x, 50x, and 80x. Since theWGA prepared samples
had higher sequence coverages, the coverage range of the
downsampled BAMs were chosen so they would closely
overlap the coverage of the original genomic DNA sample.
Due to the stochastic nature of the downsampling process,
as well as variation in capture efficiency between targets,
it was difficult to get exact match in the number of reads
between WGA and genomic BAMs. The number of reads
needed to achieve a desired coverage was determined by
solving this equation: C=(N × L)/G, where C is the cover-
age, N is the number of reads, G is the size of the genome
(in this case the total length in base pairs of capture array
targets), and L is the read length value (101 bp).
In addition to downsampling the reads from the WGA
BAMs for both capture experiments, an exact number
of read pairs were randomly sampled from the initial
WGA fastq files to match the starting number of genomic
DNA fastq read pairs. This was accomplished by writing
a Python script that randomly selects a specified number
of read pairs from a fastq file. Once the subset of fastq
read pairs were selected they were put through the same
bioinformatics pipeline applied to the original data.
Callset comparisonmetrics
We compared the variant calls from genomic and WGA
using three types of metrics. The first was site level inter-
section to see if the same genomic position was called
variant in both callsets. The other two types of metrics
were non-reference sensitivity (NRS), and non-reference
discrepancy (NRD), shown in Additional file 3: Figure S2.
NRS measures the fraction of sites called variant in the
comparison callset that are also called variant in the eval-
uation callset. For this study the evaluation callset are
the WGA variant calls and the comparison callset are
the genomic variant calls. Sites called homozygous refer-
ence or no-call in the evaluation calls, but were variant
in the comparison callset reduce NRS. NRD measures
the accuracy assigned genotypes called by both datasets.
It excludes concordant homozygous reference calls. To
calculate these values, the VCF files of the WGA and
genomic callsets were merged using the GATK program
CombineVariants and then calculated in Python. Only
sites that have PASS in the filter column of the individual
VCFs are evaluated when calculating NRS and NRD from
the CombineVariants derived VCF.
SNP validation with Affymetrix 6.0 Human SNP array
The SNP variant calls for WGA and genomic DNA for
both capture sequencing experiments were compared
to Affymetrix 6.0 Human SNP array derived genotypes
for the same samples. SNP array genotypes were called
with Birdseed v2. The 6.0 Human SNP array contains a
genomewide collection of more than 900,000 sites. For a
SNP array variant to be included in the validation anal-
ysis it must overlap a target region on the capture array
and have a confidence score of at least 0.05. Only those
variants that met these two conditions were considered.
Based on these criteria there were a total of 11831 SNPs
on the 6.0 array that overlapped the whole exome cap-
ture targets and 1435 SNPs that overlapped the custom
chr12 capture targets. Similar to the comparison of WGA
calls to genomic DNA calls, the VCFs of sequencing and
array derived genotypes were merged using the GATK
programCombineVariants. The sequencing derived geno-
types were evaluated by comparing them to the array
based genotypes and the NRS andNRD concordancemet-
rics were calculated. Only sites that have PASS in the filter
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column of the individual VCFs were included when calcu-
lating NRS and NRD from the CombineVariants derived
VCF.
Statistical analysis of allele bias in SNP calls
For both the whole-exome and chr12 capture experi-
ments, genomic andWGA SNP call sets weremerged, and
then placed into 4 categories: concordant, uniquely called
genomic, differing genotypes (NRD contributing), and
WGA uniquely called SNPs. The counts of each of the 6
possible allele combinations in each category were tallied.
To test the null hypothesis that the proportion of SNPs
are equal across all 4 categories, the pairwise.fisher.test
using the Bonferroni correction method was applied in
succession to each of the 6 possible allele combinations
in R [27]. The pairwise.fisher.test is part of the CRAN R
package fmsb [28]. The significance level α = .05 was
chosen. Additional file 5 contains an Excel sheet with
the of p-values for the whole-exome and chr12 capture
experiments.
A similar analysis was performed when comparing the
sequencing derived SNP calls to Affymetrix array derived
genotypes for genomic and WGA capture experiments.
The sequencing and Affy callsets were merged (only SNPs
on the Affymetrix array that overlapped a target cap-
ture region were included) and placed into concordant,
NRS, or NRD contributing categories. Additional file 5
has the table of p-values for the whole exome and chr12
comparisons to the array based genotypes.
Sample ascertainment
All samples and protocols for this study have been
reviewed and approved by the IRB of the Medical College
of Wisconsin. In accordance with the approved protocols,
all participants provided written informed consent to par-
ticipate in the study. Only adult individuals were included
in the study.
Additional files
Additional file 1: Excel table containing information about each of
the capture experiments. Excel table containing information about each
of the capture experiments as summarized from Picard CalculateHsMetrics.
Additional file 2: Figure S1. Boxplot of GC%. Boxplots summarizing GC%
of whole-exome and chr12 capture targets as well as overall GC% of the
whole genome and chr12 for comparison. For whole genome and whole
chromosome 12, GC% was calculated in 10 kbp windows with a 5 kbp
overlap.
Additional file 3: Figure S2. Calculating NRS and NRD genotype
concordance. Figure shows how concordance metrics of non-reference
discrepancy (NRD) and non-reference sensitivity (NRS) are calculated.
Additional file 4: Figure S3. Genotype concordance matrices. Figure
shows genotype concordance matrices for chr12 and and whole-exome
SNP and INDEL callsets from which concordance metrics of NRS and NRD
were calculated from.
Additional file 5: Excel file with results of allele bias statistical
analysis. Excel worksheet containing the computed p-values for the allele
bias statistical analysis.
Additional file 6: Figure S5. Affymetrix genotype concordance matrices
whole exome. Genotype concordance matrices of WGA and genomic DNA
SNP calls to Affymetrix genotypes for the whole exome capture experiment.
Additional file 7: Figure S6. Affymetrix genotype concordance matrices
chr12. Genotype concordance matrices of WGA and genomic DNA SNP
calls to Affymetrix genotypes for the chr12 capture experiment.
Additional file 8: Figure S4. Bioinformatics pipeline. The bioinformatics
pipeline applied to each of the genomic and WGA DNA samples for each
of the capture experiments analyzed in this study.
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